These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Is there a need for new antiarrhythmic drugs? Roden DM Arch Mal Coeur Vaiss; 1996 Feb; 89 Spec No 1():13-8. PubMed ID: 8734158 [TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of D,L-sotalol in post-ablative atrial arrhythmias in patients with atrial fibrillation treated with radiofrequency ablation]. Mihálcz A; Földesi C; Kardos A; Ladunga K; Szili-Török T Orv Hetil; 2009 Sep; 150(36):1694-700. PubMed ID: 19709984 [TBL] [Abstract][Full Text] [Related]
7. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management. Gillis AM; Verma A; Talajic M; Nattel S; Dorian P; Can J Cardiol; 2011; 27(1):47-59. PubMed ID: 21329862 [TBL] [Abstract][Full Text] [Related]
8. The role of class III antiarrhythmic agents in maintaining sinus rhythm. Brachmann J Europace; 2000 Jul; 1 Suppl C():C10-5. PubMed ID: 11220519 [TBL] [Abstract][Full Text] [Related]
9. Sotalol for cardiac arrhythmias. Med Lett Drugs Ther; 1993 Apr; 35(893):27-8. PubMed ID: 8450806 [No Abstract] [Full Text] [Related]
10. Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. Finance O; Manning A; Chatelain P J Cardiovasc Pharmacol; 1995 Oct; 26(4):570-6. PubMed ID: 8569217 [TBL] [Abstract][Full Text] [Related]
11. [Ventricular cardiac arrhythmias. New anti-arrhythmia agents]. Scholz H Z Kardiol; 1996; 85 Suppl 6():91-6. PubMed ID: 9064988 [TBL] [Abstract][Full Text] [Related]
12. A benefit-risk assessment of class III antiarrhythmic agents. Elming H; Brendorp B; Pehrson S; Pedersen OD; Køber L; Torp-Petersen C Expert Opin Drug Saf; 2004 Nov; 3(6):559-77. PubMed ID: 15500415 [TBL] [Abstract][Full Text] [Related]
13. New advances in class III antiarrhythmic drug therapy. Sager PT Curr Opin Cardiol; 2000 Jan; 15(1):41-53. PubMed ID: 10666660 [TBL] [Abstract][Full Text] [Related]
14. [Atrial flutter and fibrillation]. Scharf C Praxis (Bern 1994); 2005 Nov; 94(45):1753-9. PubMed ID: 16320889 [TBL] [Abstract][Full Text] [Related]
15. Potentially significant drug interactions of class III antiarrhythmic drugs. Yamreudeewong W; DeBisschop M; Martin LG; Lower DL Drug Saf; 2003; 26(6):421-38. PubMed ID: 12688833 [TBL] [Abstract][Full Text] [Related]
16. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Freemantle N; Lafuente-Lafuente C; Mitchell S; Eckert L; Reynolds M Europace; 2011 Mar; 13(3):329-45. PubMed ID: 21227948 [TBL] [Abstract][Full Text] [Related]
17. [Anti-arrhythmic effect of oral propafenone. Apropos of 70 cases]. Coumel P; Leclercq JF; Assayag P; Maisonblanche P; Cauchemez B Arch Mal Coeur Vaiss; 1984 Nov; 77(12):1370-82. PubMed ID: 6439161 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone. Fragakis N; Papadopoulos N; Papanastasiou S; Kozirakis M; Maligkos G; Tsaritsaniotis E; Katsaris G Pacing Clin Electrophysiol; 2005 Sep; 28(9):954-61. PubMed ID: 16176535 [TBL] [Abstract][Full Text] [Related]
19. [Present status in and prospects for anti-arrhythmic drug therapy: How to use type III anti-arrhythmic agents]. Fujiki A Nihon Naika Gakkai Zasshi; 2006 Feb; 95(2):253-60. PubMed ID: 16536075 [No Abstract] [Full Text] [Related]
20. Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs. Kowey PR; Marinchak RA; Rials SJ; Bharucha D Am J Cardiol; 1997 Oct; 80(8A):16G-23G. PubMed ID: 9354408 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]